 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1112131415161718192021...208209» |
- | HuA21 / HankeMab
New trial, Pan tumor: Safety Study of the Combination Regimen Based on HuA21 Monoclonal Antibody for the Treatment of Advanced HER2-overexpressing Solid Tumors (EUDRACT) - Jan 31, 2026
P=N/A, N=90, Not yet recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The effect of Tegileridine on postoperative pain in patients undergoing thoracoscopic lung surgery: A single-center, randomized, double-blind, controlled study (EUDRACT) - Jan 31, 2026
P=N/A, N=148, Not yet recruiting, Sponsor: The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New trial: A multicenter, randomized, parallel-group clinical study on the effects of Henagliflozin Proline Tablets and Metformin Sustained-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (EUDRACT) - Jan 31, 2026
P=N/A, N=116, Not yet recruiting, Sponsor: Huadong Hospital Affiliated to Fudan University; Huadong Hospital Affiliated to Fudan University
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Comparison of the effects of remimazolam tosilate combined with sevoflurane general anesthesia versus sevoflurane general anesthesia on postoperative sleep disturbances in patients undergoing abdominal surgery: a prospective, randomized controlled study (EUDRACT) - Jan 31, 2026
P=N/A, N=90, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital of Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: A Study on the Correlation between the Dose Differences of Remimazolam Tosilate in Patients of Different Age Groups and the Expression Quantity and Affinity of GABA Receptors (EUDRACT) - Jan 31, 2026
P=N/A, N=80, Not yet recruiting, Sponsor: Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong Science and Technology University; Tongji Hospital, Tongji Medical Col
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: Efficacy and Safety of Paclitaxel Oral Solution in Combination with Trastuzumab for Subcutaneous Injection and Pyrotinib as First-line Treatment for HER2-positive Recurrent/Metastatic Breast Cancer (EUDRACT) - Jan 31, 2026
P=N/A, N=43, Not yet recruiting, Sponsor: Beijing Cancer Hospital; Beijing Cancer Hospital
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The Effects of Tegileridine and Sufentanil on Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Cholecystectomy under Multimodal Antiemetic Strategy: A Prospective, Randomized Controlled Study (EUDRACT) - Jan 31, 2026
P=N/A, N=148, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of Dalpiciclib in the treatment of hormone receptor-positive advanced breast cancer a multicenter observational real-world study (EUDRACT) - Jan 31, 2026
P=N/A, N=500, Recruiting, Sponsor: Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New trial: The efficacy and safety of immunoradiotherapy plus gemcitabine, apatinib, and PD-L1 monoclonal antibody as first-line treatment for unresectable biliary tract tumors. (EUDRACT) - Jan 31, 2026
P=N/A, N=33, Completed, Sponsor: Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New trial: Study on the effects of SGLT2 inhibitors on proximal tubular sodium reabsorption in patients with type 2 diabetes and chronic kidney disease under different sodium dietary conditions (EUDRACT) - Jan 31, 2026
P=N/A, N=57, Not yet recruiting, Sponsor: The Fourth Medical Center of Chinese PLA General Hospital; The Fourth Medical Center of Chinese PLA General Hospital
- | Avastin (bevacizumab) / Roche, CS1002 (ipilimumab biosimilar) / CStone Pharma
New trial: A Single-Center Study to Evaluate the Efficacy and Safety of Transarterial Chemoembolization (TACE) Combined with SHR-8068, Atebolizumab, and Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (EUDRACT) - Jan 31, 2026
P=N/A, N=28, Completed, Sponsor: Lishui Central Hospital; Lishui Central Hospital
- | New trial, Circulating tumor DNA: Optimization of immunotherapy strategies for locally advanced and metastatic gastric cancer under the guidance of CTCs and ctDNA (EUDRACT) - Jan 31, 2026
P=N/A, N=200, Recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A prospective clinical study of Adebrelimab combined with chemotherapy and brain radiotherapy as the first-line treatment for extensive-stage small cell lung cancer with brain metastases (EUDRACT) - Jan 31, 2026
P4, N=28, Not yet recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Onivyde (nanoliposomal irinotecan) / Ipsen
New P4 trial: NIOFA-02: A Randomized, Open-Label Cohort Study of Adebrelimab Combined with NALIRIFOX or Gemcitabine-Cisplatin (GC) as First-Line Treatment for Locally Advanced or Metastatic Biliary Tract Cancer (EUDRACT) - Jan 31, 2026
P4, N=102, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Comparison of Tegileridine with Sufentanil in Multimodal Analgesia for Postoperative Recovery in Gynecologic Open Surgery Under the ERAS Protocol (EUDRACT) - Jan 31, 2026
P4, N=80, Not yet recruiting, Sponsor: Guangxi Medical University Cancer Hospital; Guangxi Medical University Cancer Hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Effect of Remimazolam Tosilate on Postoperative Delirium in Elderly Diabetic Patients Undergoing Orthopedic Surgery (EUDRACT) - Jan 31, 2026
P4, N=138, Not yet recruiting, Sponsor: Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P4 trial: Efficacy and Safety of an IL-1 Inhibitor in the Perioperative Period of Patients Undergoing Tophus Resection: A Single-Center, Prospective, Randomized, Positive-Controlled Study (EUDRACT) - Jan 31, 2026
P4, N=54, Not yet recruiting, Sponsor: The Fifth Hospital of Xi'an; The Fifth Hospital of Xi'an
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: The effect of tegileridine fumarate on pain scores in patients undergoing laparoscopic total hysterectomy for postoperative pain management (EUDRACT) - Jan 31, 2026
P4, N=16, Not yet recruiting, Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
- | HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P4 trial: Analysis of Efficacy and Risk Factors for Primary Prevention of Neutropenia in Cancer Patients Under Standardized Nutritional Intervention (EUDRACT) - Jan 31, 2026
P4, N=100, Recruiting, Sponsor: Anqing First People's Hospital; Anqing First People's Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P4 trial: Adebrelimab and famitinib alone or combined with short-course chemotherapy as the first-line treatment for PD-L1-positive advanced non-small cell lung cancer: a clinical study (EUDRACT) - Jan 31, 2026
P4, N=80, Not yet recruiting, Sponsor: Changzhou First People's Hospital; Changzhou First People's Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Effects of Tegileridine used for postoperative analgesia on the quality of postoperative recovery in elderly patients with colorectal tumors (EUDRACT) - Jan 31, 2026
P4, N=92, Not yet recruiting, Sponsor: Guangxi Medical University Cancer Hospital; Guangxi Medical University Cancer Hospital
- | Ensacove (ensartinib) / Betta Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
New P4 trial: Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star) (EUDRACT) - Jan 31, 2026
P4, N=598, Recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: A randomized, double-blinded, placebo-controlled clinical trial of the efficacy and safety of SHR-0302 combine with Prednisone Acetate in the treatment of active arteritis (EUDRACT) - Jan 31, 2026
P4, N=58, Not yet recruiting, Sponsor: Zhongshan hospital, Fudan University; Zhongshan hospital, Fudan University
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P4 trial: Efficacy and Safety of Herombopag Ethanolamine Tablets in Combination with Cyclosporine and Androgen for the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) Patients (EUDRACT) - Jan 31, 2026
P4, N=42, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Research on the Effects of the Novel Analgesic Tegileridine on Perioperative Neurocognitive Function and Its Mechanisms (EUDRACT) - Jan 31, 2026
P4, N=474, Not yet recruiting, Sponsor: Jiangsu Province People's Hospital; Jiangsu Province People's Hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Real-world study of the quality of recovery from general anesthesia using Remimazolam Tosilate Injection (EUDRACT) - Jan 31, 2026
P4, N=625, Recruiting, Sponsor: Xiangya Hospital Central South University; Xiangya Hospital Central South University
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: A Comparative Evaluation of the Safety and Efficacy of Tegileridine and Sufentanil in Gastrointestinal Endoscopy: A Single-Center, Randomized Controlled Trial. (EUDRACT) - Jan 31, 2026
P4, N=676, Not yet recruiting, Sponsor: Xiangyang Central Hospital; Xiangyang Central Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P4 trial: An Open-Label, Randomized Controlled, Phase III Study of Dalpiciclib Plus Endocrine Therapy Versus Chemotherapy Followed by Endocrine Therapy in High-Risk HR+/HER2- Recurrent or Metastatic Breast Cancer (EUDRACT) - Jan 31, 2026
P4, N=220, Not yet recruiting, Sponsor: Cancer Hospital of Shandong First Medical University; Cancer Hospital of Shandong First Medical University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: A Study on the Efficacy and Safety of Tegileridine Fumarate for Postoperative Analgesia after Thoracoscopic Surgery (EUDRACT) - Jan 31, 2026
P4, N=60, Not yet recruiting, Sponsor: Henan Provincial People's Hospital; Henan Provincial People's Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial: A prospective, multicenter, single-arm clinical study of NASOX in combination with camrelizumab for neoadjuvant/conversion therapy of pancreatic cancer (EUDRACT) - Jan 31, 2026
P4, N=40, Not yet recruiting, Sponsor: The first people's Hospital of Yunnan Province; The first people's Hospital of Yunnan Province
- | Nucynta (tapentadol) / Collegium Pharma, Grunenthal
New P4 trial: Effects of Tapentadol on Gastrointestinal Function Recovery in Patients After Lumbar Spine Surgery (EUDRACT) - Jan 31, 2026
P4, N=134, Not yet recruiting, Sponsor: Shunde Hospital, Guangzhou University of Chinese Medicine; Shunde Hospital, Guangzhou University of Chinese Medicine
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Comparison of postoperative Analgesia given Sufentanil or Tegileridine in Laparoscopic Cholecystectomy, a prospective, randomized, controlled, blinded study (EUDRACT) - Jan 31, 2026
P4, N=240, Not yet recruiting, Sponsor: Puyang Oil Field General Hospital; Puyang Oil Field General Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Efficacy and Safety of tegileridine combined with paravertebral block for postoperative pain management in gastric cancer patients (EUDRACT) - Jan 31, 2026
P4, N=100, Not yet recruiting, Sponsor: Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: The impact of remimazolam tosylate for injection on intraoperative stress response and postoperative cognitive function in elderly patients undergoing ERCP (EUDRACT) - Jan 31, 2026
P4, N=60, Completed, Sponsor: Shandong Provincial Third Hospital; Shandong Provincial Third Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Tegileridine improves postoperative pain in patients undergoing day surgery for laparoscopic cholecystectomy: A randomized controlled trial (EUDRACT) - Jan 31, 2026
P4, N=56, Not yet recruiting, Sponsor: The Third People's Hospital Yibin; The Third People's Hospital Yibin
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Establishing the Median Effective Doses of Tegileridine for Immediate Post-Surgical Analgesia Following Laparoscopic Colorectal Cancer Surgery: A Sequential Dose-Finding Study (EUDRACT) - Jan 31, 2026
P4, N=40, Not yet recruiting, Sponsor: Shanghai Changhai Hospital; Shanghai Changhai Hospital
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: Henagliflozin for the Treatment of Patients with T2DM and CKD: A Real-World, Multicenter Case Registry Study (EUDRACT) - Jan 31, 2026
P4, N=1000, Completed, Sponsor: The 2nd Affiliated Hospital of Chongqing Medical University; The 2nd Affiliated Hospital of Chongqing Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial: Personalized Tumor Model-Guided Therapy for Peritoneal Mesothelioma (EUDRACT) - Jan 31, 2026
P3, N=347, Not yet recruiting, Sponsor: Tsinghua University affiliated Beijing Tsinghua Changgung Hospital; Tsinghua University affiliated Beijing Tsinghua Changgung Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A prospective study of bipolar androgen followed by novel AR inhibitors combined with PD-1 inhibitors in the treatment of mCRPC (EUDRACT) - Jan 31, 2026
P3, N=30, Recruiting, Sponsor: Beijing Hospital; Beijing Hospital
- | SYS6010 / CSPC Pharma, Enshuxing (enlonstobart) / CSPC Pharma, Sumgen Biotech
New P2/3 trial: Phase II/III Trial of SYS6010 plus Enlonstobart Injection (EUDRACT) - Jan 31, 2026
P2/3, N=737, Not yet recruiting, Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A single-arm, open-label clinical study of adebelimab in combination with apatinib mesylate and irinotecan in the treatment of advanced second-line esophageal cancer (EUDRACT) - Jan 31, 2026
P2, N=32, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: An Exploratory Study of Liposomal Irinotecan (II) Combined with Apatinib in Soft Tissue Sarcoma After Failure of Standard Treatment (EUDRACT) - Jan 31, 2026
P2, N=28, Recruiting, Sponsor: The First Medical Center of Chinese PLA General Hospital; The First Medical Center of Chinese PLA General Hospital
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P2 trial: A randomized, controlled, multicenter clinical study of SHR-A1811 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer. (EUDRACT) - Jan 31, 2026
P2, N=80, Not yet recruiting, Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | zeprumetostat (SHR-2554) / Treeline Biosci, Duoenda (mitoxantrone liposomal) / CSPC Pharma
New P2 trial: Clinical Study on the Efficacy and Safety of Zeprumetostat, Azacitidine Combined with Lipo-MIT in Relapsed/Refractory Peripheral T-Cell Lymphoma. (EUDRACT) - Jan 31, 2026
P2, N=26, Not yet recruiting, Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II, Multicenter, Randomized, single-Blind, Dose exploration, Positive Comparator Study to Evaluate the Efficacy and Safety of Tegileridine Fumarate lnjection for prolonged mechanical ventilation abirritation in the intensive care unit (ICU) (EUDRACT) - Jan 31, 2026
P2, N=120, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Exploratory Study of Adebrelimab Combined with GP Regimen as First-Line Therapy for Advanced Intrahepatic Cholangiocarcinoma (EUDRACT) - Jan 31, 2026
P2, N=30, Not yet recruiting, Sponsor: Eastern Theater Command General Hospital of the People's Liberation Army; Eastern Theater Command General Hospital of the People's Liberation Army
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Phase II Study of PD-1 Monoclonal Antibody Combined with Apatinib, With or Without Chemotherapy, as Maintenance Therapy for Patients with Advanced Driver Gene-Negative NSCLC Who Have Not Progressed (EUDRACT) - Jan 31, 2026
P2, N=86, Not yet recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab plus Rivoceranib as first-line maintenance therapy after Camrelizumab-Chemo induction in advanced esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (EUDRACT) - Jan 31, 2026
P2, N=38, Not yet recruiting, Sponsor: The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University
- | HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P2 trial: An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Efficacy and Safety of mecapegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Breast Cancer (EUDRACT) - Jan 31, 2026
P2, N=48, Not yet recruiting, Sponsor: Beijing Cancer Hospital; Beijing Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A single-center, open-label, Phase II study of Adebrelimab Injection in combination with albumin-paclitaxel and cisplatin for neoadjuvant treatment of resectable oral squamous cell carcinoma (EUDRACT) - Jan 31, 2026
P2, N=30, Not yet recruiting, Sponsor: Hunan Cancer Hospital; Hunan Cancer Hospital